Blog | Insights on drug delivery & innovation

Moving faster, with confidence: An interview with Ulrike Bauer, Chief Business Officer at Ypsomed

How can pharma and biotech companies accelerate drug-device programs without shifting risk or bottlenecks further downstream? In this interview, Ypsomed Chief Business Officer Ulrike Bauer discusses how platform flexibility, device readiness and …

For the record: How past experience enables future success

Jakob Lange and Shawn James discuss the value of the experience hidden behind metrics such as completed projects and commercialized devices – the wealth of accumulated process knowledge that enables a company to bring hard-learned lessons forwards.

Biobased plastics in drug delivery: From material equivalence to systemic decarbonization

Biobased plastics can cut carbon without changing performance or regulatory status. In our latest blog, Nadine Kaufmann and Michael Schori explore how material equivalence, lifecycle thinking, and scale enable real decarbonization in drug delivery …

The compass for innovation: Regulatory Affairs at Ypsomed

Acting as the compass for innovation, Ypsomed’s regulatory strategy steers ideas through development to deliver safe, compliant solutions to patients worldwide.

Self-injection device manufacturing in a dynamic world

How did pen-inspired injectors evolve into today’s flexible self-injection platforms? Discover the trends in usability, scale-up, and resilient manufacturing that are shaping the future of drug delivery in a fast-changing industry landscape.

Sustainable GLP-1 drug delivery

GLP-1 therapies are entering a high-growth phase, driving demand for scalable, sustainable delivery solutions. As formulations evolve, device usability, and environmental impact becomes a key industry challenge.

A fresh look at how patients interact with pen injectors

How do patients handle pen injectors, and what forces do they apply during use? How can these findings shape the design of future devices to improve comfort and usability, especially for those with dexterity challenges?

Ypsomed’s platform product transformation and approach to strategic partner networking

Over the last 40 years, we have been at the forefront of the development and manufacturing of self-injection systems. How has Ypsomed transformed the market for platform-based self-injection devices?

First Deliveries of YpsoMate 1 mL as part of the NetZero Program

Ypsomed supplied first batches of YpsoMate 1 mL with a reduced carbon footprint as part of the NetZero Program in 2023 . This milestone is a key step in the transformation of the platform proven YpsoMate autoinjector into a zero-carbon emission …

Welcome to the Ypsomed Blog